SK Biopharmaceuticals struck an exclusive worldwide license with the Wisconsin Alumni Research Foundation (WARF) to develop, manufacture and commercialize WT‑7695, a preclinical radiopharmaceutical developed with the University of Wisconsin–Madison. The deal transfers global rights for R&D and commercialization to SK Biopharma, signaling continued industry focus on radioligand therapies and targeted radiopharmaceuticals for oncology. SK will advance preclinical programs and position WT‑7695 for IND‑enabling studies, leveraging WARF’s technology to enter the growing radiopharma market.